the aid library

LIST OPTIONS

Filter

10741

The Global strategy and action plan on ageing and health

World Health Organization WHO (2017) C_WHO

Specifically the Strategy focuses on five strategic objectives: commitment to action on Healthy Ageing in every country; developing age-friendly environments; aligning health systems to the needs of older populations; developing sustainable and equitable systems for providing lon... more

Download (291)

View PDF (311)

National Antenatal Sentinel HIV Survey Key Findings, South Africa 2017

south (2019) CC

Download (327)

View PDF (293)

Antiepileptic drug therapy in individuals with intellectual disability & epilepsy

World Health Organization (2012) C_WHO

Q12: Should the treatment be similar in individuals with intellectual disability and epilepsy compared to people with epilepsy only?

Download (367)

View PDF (279)

Курение табака через кальян и последствия для здоровья

World Health Organization World Health Organization (2015) C_WHO

информационный листок о курении табака через кальян и последствиях для здоровья

Download (229)

View PDF (348)

The Burden of Pediatric Asthma

Ferrante, G.; La Grutta, S. Frontiers in Pediatrics (2018) CC

Asthma is the most common chronic disease in children, imposing a consistent burden on health system. In recent years, prevalence of asthma symptoms became globally increased in children and adolescents, particularly in Low-Middle Income Countries (LMICs). Host (genetics, atopy) and environmental fa... more

Download (318)

View PDF (225)

National hiv testing services communication strategy 2015 - 2019

National AIDS STI Control Programme (NASCOP), Ministry of Health, Government of Kenya (2015) C1

Strategic communication is used to raise awareness of issues among specific target populations. It aims to provide timely, evidence-based, authoritative information and guidance needed for public health action. Proper implementation of strategic communication leads t... more

Download (414)

View PDF (362)

Monitoring and surveillance of antimicrobial resistance in bacteria from healthy food animals intended for consumption

Food and Agriculture Organization of the United Nations FAO (2019) C2

The animal health subsector within the agriculture sector is the gatekeeper of antimicrobial resistance (AMR) in livestock, aquaculture, animal products, and the immediate animal environment. In support of member countries taking responsibility for and moving forward with putting AMR monitoring and ... more

Download (459)

View PDF (646)

Living Conditions among People with Activity Limitations in Zambia: A National Representative Study.

Arne H Eide & ME Loeb SINTEF Health Research (2006) C1

This research report provides results from the study on living conditions among people with disabilities in Zambia. Comparisons are made between individuals with and without disabilities and also between households with and without a disabled family member. Results obtained in Zambia are also compar... more

Download (1944)

View PDF (2268)

Kenya HIV Prevention Revolution Road Map. Countdown to 2030

Ministry of Health, Kenya (2014) C1

Download (927)

View PDF (1128)

Namibia: National Public Health Laboratory Strategic Plan

Ministry of Health and Social Services (MOHSS) (2012) C1

Download (390)

View PDF (463)

Global vaccine safety blueprint 2.0 (GVSB2.0) 2021-2023

World Health Organization WHO (2022) C_WHO

Download (695)

View PDF (1226)

Yellow fever situation report (28 October 2016)

World Health Organization WHO (2016) C_WHO

Download (165)

View PDF (140)

Evaluation of serum-based real-time PCR to detect Schistosoma mansoni infection before and after treatment

Fuss, A.; H. D. Mazigo and A. Mueller (2020) CC

Infectious Diseases of Poverty (2020) 9:74 To detect acute schistosomiasis, low-intensity infections, or to verify the success of treatment with praziquantel, highly sensitive test methods are required. The aim of this study was therefore to demonstrate the performance of Schistosoma mansoni spec... more

Download (519)

View PDF (546)

Introducing and scaling up testing for human papillomavirus as part of a comprehensive programme for prevention and control of cervical cancer

World Health Organization WHO (2020) C_WHO

This guidance is intended to be used by programme managers following the decision to introduce human papillomavirus (HPV) virological testing as a screening assay in their national cervical cancer prevention and control programme. The guidance includes a step-by-step process to be followed after the... more

Download (289)

View PDF (372)

COVID-19: Guidelines for communicating about coronavirus disease 2019 - A guide for leaders

Pan American Health Organisation PAHO (2020) C_WHO

Risk communication encompasses all the basics of health communication but differs in the need for speed and reliance on trust. At times of crisis, leaders are called on to provide a quick, sensitive and trustworthy response.

External Link

Guide to introducing human rabies vaccine into national immunization programmes: Handbook

World Health Organization WHO (2022) C_WHO

Rabies is fatal, vaccine-preventable disease responsible for an estimated 59,000 human deaths each year. Most cases are transmitted by dogs, and most deaths occur in underserved populations in Africa and Asia. Approximately 40% of deaths occur in children.

Download (255)

View PDF (431)

Pediatric oncology nursing practice in Latin America and the Caribbean

Pan American Health Organisation PAHO (2024) C_WHO

One of the main aims of the WHO Global Initiative for Childhood Cancer and the CureAll Americas framework is to strengthen centers of excellence and promote the training of the health workforce, especially pediatric oncology nurses, specialized in nursing care for children and adolescents with cance... more

Download (859)

View PDF (1876)

Guidance on oral pre-exposure prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV: recommendations for use in the context of demonstratio

World Health Organization (2012)

Download (339)

View PDF (352)

EMTCT Plus - Framework for Elimination of Mother-to-Child Transmission of HIV, Syphilis, Hepatitis B, and Chagas

F. Pérez; M. B. Mello; L. Sereno; et al. Pan American Health Organization; World Health Organization (2017) C_WHO

The objective of the EMTCT Plus initiative is to achieve and sustain the elimination of mother-to-child transmission of HIV, syphilis, Chagas, and perinatal hepatitis B (HBV) as a public health threat. It embraces the principles and lines of action of the Strategy for Universal Access to Health a... more

Download (481)

View PDF (707)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more